Literature DB >> 24204015

Serum- and glucocorticoid-regulated kinase 2 determines drug-activated pregnane X receptor to induce gluconeogenesis in human liver cells.

Saki Gotoh1, Masahiko Negishi.   

Abstract

Drug activation of the human nuclear pregnane X receptor (PXR) induced gluconeogenic genes and increased glucose production. In this study, we have determined that serum- and glucocorticoid-regulated kinase 2 (SGK2) is an essential factor that mediates this PXR-regulated glucose 6-phosphatase (G6Pase) induction and glucose production. Both SGK2 and G6Pase mRNAs were increased in rifampicin-treated HepG2 cells stably expressing human PXR. Reporter and chromatin immunoprecipitation assays delineated PXR activation of the SGK2 gene to a distal and proximal DNA sequence within its promoter: distal PXR response element (-2587/-2209) and proximal PXR response element (-115/-75), respectively. Small interfering RNA (siRNA) knockdown of SGK2 severely attenuated PXR-regulated induction of G6Pase as well as glucose production. SGK2 constitutes an insulin-independent signal pathway to regulate gluconeogenesis because siRNA knockdown of the insulin-responsive transcription factor forkhead box protein O1 did not affect rifampicin induction of G6Pase. Rifampicin treatment of two different samples of human primary hepatocytes revealed that PXR induces G6Pase in the presence of high levels of SGK2, whereas PXR represses G6Pase in its absence. Mediating PXR activation of the G6Pase gene is the first biological role found for hepatic SGK2 and might have therapeutic implications for side effects, such as diabetes, caused by drugs that activate PXR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24204015      PMCID: PMC3868883          DOI: 10.1124/jpet.113.209379

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

1.  Impaired renal Na(+) retention in the sgk1-knockout mouse.

Authors:  Peer Wulff; Volker Vallon; Dan Yang Huang; Harald Völkl; Fang Yu; Kerstin Richter; Martina Jansen; Michaela Schlünz; Karin Klingel; Johannes Loffing; Gunther Kauselmann; Michael R Bösl; Florian Lang; Dietmar Kuhl
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase.

Authors:  T Kobayashi; M Deak; N Morrice; P Cohen
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

3.  Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.

Authors:  M Niemi; J T Backman; M Neuvonen; P J Neuvonen; K T Kivistö
Journal:  Clin Pharmacol Ther       Date:  2001-06       Impact factor: 6.875

4.  Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2.

Authors:  T Kobayashi; P Cohen
Journal:  Biochem J       Date:  1999-04-15       Impact factor: 3.857

5.  Drug interaction: rifampicin and glibenclamide.

Authors:  V Surekha; J V Peter; L Jeyaseelan; A M Cherian
Journal:  Natl Med J India       Date:  1997 Jan-Feb       Impact factor: 0.537

6.  Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes.

Authors:  Susumu Kodama; Chika Koike; Masahiko Negishi; Yukio Yamamoto
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

Review 7.  Sgk kinases and their role in epithelial transport.

Authors:  Johannes Loffing; Sandra Y Flores; Olivier Staub
Journal:  Annu Rev Physiol       Date:  2006       Impact factor: 19.318

8.  Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.

Authors:  Ji-Young Park; Kyoung-Ah Kim; Pil-Whan Park; Chan-Woong Park; Jae-Gook Shin
Journal:  Clin Pharmacol Ther       Date:  2003-10       Impact factor: 6.875

9.  Rifampicin-induced early phase hyperglycemia in humans.

Authors:  N Takasu; T Yamada; H Miura; S Sakamoto; M Korenaga; K Nakajima; M Kanayama
Journal:  Am Rev Respir Dis       Date:  1982-01

10.  Regulation of glucose transporter SGLT1 by ubiquitin ligase Nedd4-2 and kinases SGK1, SGK3, and PKB.

Authors:  Michael Dieter; Monica Palmada; Jeyaganesh Rajamanickam; Atakan Aydin; Andreas Busjahn; Christoph Boehmer; Friedrich C Luft; Florian Lang
Journal:  Obes Res       Date:  2004-05
View more
  13 in total

Review 1.  The Roles of Xenobiotic Receptors: Beyond Chemical Disposition.

Authors:  Bryan Mackowiak; Jessica Hodge; Sydney Stern; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2018-05-14       Impact factor: 3.922

Review 2.  Regulation of PXR and CAR by protein-protein interaction and signaling crosstalk.

Authors:  Peter Oladimeji; Hongmei Cui; Chen Zhang; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-06-23       Impact factor: 4.481

Review 3.  Nuclear receptor phosphorylation in xenobiotic signal transduction.

Authors:  Masahiko Negishi; Kaoru Kobayashi; Tsutomu Sakuma; Tatsuya Sueyoshi
Journal:  J Biol Chem       Date:  2020-08-11       Impact factor: 5.157

4.  Statin-activated nuclear receptor PXR promotes SGK2 dephosphorylation by scaffolding PP2C to induce hepatic gluconeogenesis.

Authors:  Saki Gotoh; Masahiko Negishi
Journal:  Sci Rep       Date:  2015-09-22       Impact factor: 4.379

Review 5.  Pregnane X Receptor (PXR)-Mediated Gene Repression and Cross-Talk of PXR with Other Nuclear Receptors via Coactivator Interactions.

Authors:  Petr Pavek
Journal:  Front Pharmacol       Date:  2016-11-25       Impact factor: 5.810

6.  Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo.

Authors:  Nikolaos Nikolaou; Anastasia Arvaniti; Nathan Appanna; Anna Sharp; Beverly A Hughes; Dena Digweed; Martin J Whitaker; Richard Ross; Wiebke Arlt; Trevor M Penning; Karen Morris; Sherly George; Brian G Keevil; Leanne Hodson; Laura L Gathercole; Jeremy W Tomlinson
Journal:  J Endocrinol       Date:  2020-05       Impact factor: 4.286

7.  PXR Functionally Interacts with NF-κB and AP-1 to Downregulate the Inflammation-Induced Expression of Chemokine CXCL2 in Mice.

Authors:  Maya Okamura; Ryota Shizu; Taiki Abe; Susumu Kodama; Takuomi Hosaka; Takamitsu Sasaki; Kouichi Yoshinari
Journal:  Cells       Date:  2020-10-15       Impact factor: 6.600

Review 8.  PXR and 4β-Hydroxycholesterol Axis and the Components of Metabolic Syndrome.

Authors:  Janne Hukkanen; Jukka Hakkola
Journal:  Cells       Date:  2020-11-09       Impact factor: 6.600

9.  Serum- and glucocorticoid-induced kinase drives hepatic insulin resistance by directly inhibiting AMP-activated protein kinase.

Authors:  Ben Zhou; Yuyao Zhang; Sainan Li; Lianfeng Wu; Geza Fejes-Toth; Aniko Naray-Fejes-Toth; Alexander A Soukas
Journal:  Cell Rep       Date:  2021-10-05       Impact factor: 9.423

10.  Natural substance rutin versus standard drug atorvastatin in a treatment of metabolic syndrome-like condition.

Authors:  Dominika Micháliková; Barbara Tyukos Kaprinay; Boris Lipták; Karol Švík; Lukáš Slovák; Ružena Sotníková; Vladimír Knezl; Zdenka Gaspárová
Journal:  Saudi Pharm J       Date:  2019-10-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.